Company profilePharmaceutical#63 of 1,318 in Pakistan10 DRAP alerts

WILSONS PHARMACEUTICALS

Pharmaceutical company · 217 brands · 265 molecules

Ranked #14 of 70 companies in Cardiac Care

217 registered products 64 pharmaceutical brands 265 distinct molecules 10 DRAP alerts

Company overview

217
registered products
64
pharmaceutical brands
265
distinct molecules
12
therapeutic classes
10
DRAP alerts

WILSONS PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 217 product registrations across 265 distinct molecules. It is the 63rd largest registrant in Pakistan by product count, and ranks 14th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Angiotensin-Ii Antagonists, Combinations. DRAP has issued 10 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by WILSONS

172 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) 5

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

116
ceilings with an approval date
7
not revised in 2+ years
2024
oldest approval year
20247
2025105
20264
Longest without revision

Top molecules by brand count

Nutritional Supplement / Multivitamin23 brands
Amlodipine8 brands
Paracetamol6 brands
Nicotinamide6 brands
Pyridoxine6 brands
Riboflavin6 brands
Thiamine6 brands
Calcium6 brands
Enalapril5 brands

Therapeutic classes

Cardiac Care · 8Angiotensin-Ii Antagonists, Combinations · 8Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 6Other Calcium Supplements · 5Blood Glucose Lowering Drugs, Excluding Insulin · 4Lipid Modifying Agents · 4Gastro · 4Quinolone Antibacterials · 4Antiinflammatory And Antirheumatic Products · 4Fever/Flu/Cough · 3Pain Management · 3Antipsoriatics · 2

Conditions treated

Hypertension · 6Ulcer/Reflux/Flatulence/Acidity · 4Cold/Cough/Flu · 2High Cholestrol · 1Anaemia · 1Scabies · 1Heart Failure · 1Fever/Pain/Flu · 1Pain Killers · 1Arthritis · 1Hyperpigmentation · 1General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official114 products · Rs 52.26 – Rs 19,004.31
DVAGO39 products · Rs 22.8 – Rs 1,197
Servaid43 products · Rs 55.16 – Rs 1,500
Median across source: Rs 310.48

Regulatory record

10 alerts in the DRAP feed we track.

Safety Alert risk of severe chemical irritation and damage to tissues with Promethazine hy
2025-04-07
Recall Alert: Drug Product; Novarise 50mg/5ml Syrup by Sharooq Pharmaceuticals, Lahore
2024-05-16
Recall Alert; Drug Products: Mebzole 100mg/5mL Suspension and Bioris 1mg/ml Oral Solution
2024-04-29
Recall Alert; 03 Batches of Veterinary Drug Products by M/s Biolabs Pvt., Ltd., Islamabad
2024-04-28
Recall Alert; Drug Products: Artecid 75mg/3mL Injections by M/s Biolabs Pvt., Ltd., Islama
2024-04-28
Rapid Alert: Contaminated Propylene Glycol (Batch #C815N3OR41) Allegedly Produced by Dow C
2024-01-11
Safety Alert: WHO Global Alert on Tetracycline Hydrochloride Ophthalmic Ointment USP 1%
2023-03-06
Drug Safety Alert: Risk of Reduced Vitamin B12 Level with Metformin and Metformin-Containi
2022-11-25

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Werrick Pharmaceuticals Pakistan holds 79 molecules not in this portfolio
AcetazolamideAlendronateAlprazolamAmoxycillinArtemetherAtenolol
Atco Pharma International (Pvt) Ltd holds 189 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAminophyllineAmlodipine 6.95Mg Amlodipine Base
SEARLE PAKISTAN (PVT.) LTD. holds 183 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for WILSONS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.